GSK to cap out-of-pocket inhaler costs in US

British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United States, following similar moves by two of its rivals.

 

Also Read: Complaints over separatist views of new British Sikh BBC presenter

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)